• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation.

作者信息

Lacasse F X, Hildgen P, Pérodin J, Escher E, Phillips N C, McMullen J N

机构信息

Faculty of Pharmacy, University of Montréal, Québec, Canada.

出版信息

Pharm Res. 1997 Jul;14(7):887-91. doi: 10.1023/a:1012147700014.

DOI:10.1023/a:1012147700014
PMID:9244145
Abstract

PURPOSE

To characterize and evaluate in vitro and in vivo the release mechanisms involved in spray-dried biodegradable microspheres having different Poly(D,L-lactide) blend formulations and containing an antihypertensive drug (L-158,809).

METHODS

Microspheres and blended polymers were characterized by DSC, SEM, confocal laser microscopy and size analysis. In vitro release studies were evaluated by using microspheres made from various blends of high and low molecular weight polymer. In vivo studies were evaluated by L-158,809 antagonist AT1 function versus the shift of the normal dose-response curve of blood pressure induced by Angiotensine II.

RESULTS

The average yield of L-158,809 microspheres (10% (w/w)) was 95% of the theoretical loading. The average diameter of the microspheres was from 1 to 3 micrometers. In all release experiments, a significant burst effect (< 15%) was observed followed by a near zero-order release kinetics. In vivo studies with two different formulations show a strong shift of angiotensin II dose-response curve.

CONCLUSIONS

The release kinetics and photomicrographs suggest that the system is best described as a multi-parameter controlled released system in which the drug is molecularly dispersed. In vivo results demonstrating the controlled release of L-158,809.

摘要

相似文献

1
Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation.
Pharm Res. 1997 Jul;14(7):887-91. doi: 10.1023/a:1012147700014.
2
Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.新型非肽类AT1受体拮抗剂SK-1080所表现出的血管紧张素II拮抗作用的特性
J Cardiovasc Pharmacol. 1999 Mar;33(3):367-74. doi: 10.1097/00005344-199903000-00004.
3
Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist.新型非肽类血管紧张素II受体拮抗剂KT3-671的药理特性
J Cardiovasc Pharmacol. 1995 Jan;25(1):22-9. doi: 10.1097/00005344-199501000-00005.
4
Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.新型非肽类AT1受体拮抗剂KR-30988在大鼠、兔和犬体内的药理学特性研究
J Pharm Pharmacol. 1999 Oct;51(10):1191-200. doi: 10.1211/0022357991776732.
5
Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis.可生物降解微球表面性质的影响:对血浆蛋白吸附和吞噬作用的影响。
Pharm Res. 1998 Feb;15(2):312-7. doi: 10.1023/a:1011935222652.
6
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.新型非肽类血管紧张素II受体拮抗剂UP 269-6的体内药理学特性
Eur J Pharmacol. 1995 Sep 15;284(1-2):157-70. doi: 10.1016/0014-2999(95)00395-2.
7
The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist.新型血管紧张素II受体拮抗剂606A的药理学概况。
J Cardiovasc Pharmacol. 1997 Feb;29(2):284-90. doi: 10.1097/00005344-199702000-00019.
8
Differential development of angiotensin II receptor subtypes in the rat brain.大鼠脑中血管紧张素 II 受体亚型的差异发育
Endocrinology. 1991 Jan;128(1):630-2. doi: 10.1210/endo-128-1-630.
9
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.血管紧张素II受体拮抗剂依普罗沙坦可抑制交感神经传出,但氯沙坦、缬沙坦或厄贝沙坦则无此作用:与节前血管紧张素II受体阻滞差异的关系。
Pharmacology. 1997 Nov;55(5):244-51. doi: 10.1159/000139534.
10
Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes.血管紧张素II受体阻滞剂可减轻糖尿病足细胞中血管内皮生长因子的过度表达。
Exp Mol Med. 2004 Feb 29;36(1):65-70. doi: 10.1038/emm.2004.9.

引用本文的文献

1
Methods to assess in vitro drug release from injectable polymeric particulate systems.评估可注射聚合物微粒系统体外药物释放的方法。
Pharm Res. 2006 Mar;23(3):460-74. doi: 10.1007/s11095-005-9397-8. Epub 2006 Jan 13.
2
Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying.达贝泊汀α聚乳酸-羟基乙酸共聚物微球制剂:喷雾干燥是替代喷雾冻干粉化包封的方法。
Pharm Res. 2004 Mar;21(3):500-6. doi: 10.1023/B:PHAM.0000019305.79599.a5.
3
Preparation of gelatin microbeads with a narrow size distribution using microchannel emulsification.

本文引用的文献

1
Carcinogenic studies on water-soluble and insoluble macromolecules.
AMA Arch Pathol. 1959 Jun;67(6):589-617.
2
Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles?低分子量聚乳酸:一种适用于肺部给药微粒的聚合物?
J Microencapsul. 1993 Apr-Jun;10(2):195-207. doi: 10.3109/02652049309104385.
3
Anti-angiotensin antibodies cross-reactive with nonpeptide angiotensin antagonists as angiotensin receptor model.与非肽类血管紧张素拮抗剂交叉反应的抗血管紧张素抗体作为血管紧张素受体模型。
使用微通道乳化法制备粒径分布窄的明胶微珠。
AAPS PharmSciTech. 2002;3(3):E25. doi: 10.1208/pt030325.
4
Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis.可生物降解微球表面性质的影响:对血浆蛋白吸附和吞噬作用的影响。
Pharm Res. 1998 Feb;15(2):312-7. doi: 10.1023/a:1011935222652.
Regul Pept. 1993 Mar 19;44(2):239-47. doi: 10.1016/0167-0115(93)90248-7.
4
Piroxicam release from spray-dried biodegradable microspheres.
Biomaterials. 1994 Jan;15(1):49-54. doi: 10.1016/0142-9612(94)90196-1.
5
Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin-, and potassium-stimulated aldosterone secretion.
Hypertension. 1995 Mar;25(3):443-8. doi: 10.1161/01.hyp.25.3.443.
6
Influence of N omega-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation.Nω-硝基-L-精氨酸甲酯、LY83583、格列本脲和L158809对肺循环的影响。
Eur J Pharmacol. 1994 Sep 22;263(1-2):133-40. doi: 10.1016/0014-2999(94)90533-9.
7
Anti-hypertensive effect of oral controlled-release microspheres containing an ACE inhibitor (delapril hydrochloride) in rats.含血管紧张素转换酶抑制剂(盐酸地拉普利)的口服控释微球对大鼠的降压作用
J Pharm Pharmacol. 1994 Aug;46(8):661-5. doi: 10.1111/j.2042-7158.1994.tb03878.x.
8
Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism.功能研究而非受体结合能够区分可克服的与不可克服的AT1拮抗作用。
J Pharmacol Exp Ther. 1995 May;273(2):753-61.
9
Quality improvement of spray-dried, protein-loaded D,L-PLA microspheres by appropriate polymer solvent selection.通过适当选择聚合物溶剂提高喷雾干燥的载蛋白D,L-聚乳酸微球的质量
J Microencapsul. 1995 Jan-Feb;12(1):83-97. doi: 10.3109/02652049509051129.
10
Non-peptide angiotensin receptor antagonists bind to tachykinin NK3 receptors of rat and guinea pig brain.非肽类血管紧张素受体拮抗剂与大鼠和豚鼠脑内的速激肽NK3受体结合。
Eur J Pharmacol. 1994 Apr 11;256(1):73-8. doi: 10.1016/0014-2999(94)90618-1.